SITE MAP
- LET THE FDA KNOW ABOUT YOUR EXPERIENCE LIVING WITH PV, ET OR MF!
- JOANN MASON ATTENDS MPN ROUNDTABLE IN CHICAGO
- MPN UPDATES FROM ASCO 2019
- MPNRF’S EXECUTIVE DIRECTOR DISCUSSES THE INTERFERON INITIATIVE
- NEW CLINICAL TRIALS AVAILABLE FOR MPN PATIENTS
- MPNRF celebrates 1st annual Founder’s Day
- SIERRA ONCOLOGY LAUNCHES THE MOMENTUM PHASE 3 CLINICAL TRIAL FOR PATIENTS WITH MYELOFIBROSIS
- JANUARY NEW DONOR CHALLENGE
- IDENTIFICATION OF TET2 AND CALR
- Understanding MPNS
- Myelofibrosis
- Essential thrombocythemia (ET)
- Polycythemia Vera (PV)
- GLOSSARY
- Our Mission and History
- About MPNRF
- Board of Directors
- MPNRF Team
- Scientific Advisory Board
- Our Research Impact
- Meet our MPN Community Partners
- Living with an MPN
- Financials
- JUST DIAGNOSED
- Find support
- TREATMENTS
- Blog
- Patient’s Bill of Rights
- MPN CLINICAL TRIALS
- Patient & caregiver stories
ABOUT US
- MPD Foundation President, Bob Rosen, attends 2004 ASH Conference in San Diego, California
- LETTER FROM THE PRESIDENT
- I5 WEEKS AFTER HEALTH COLLAPSE, COACH BACK IN BELOVED ROUTINE
- MPD FOUNDATION FUNDS RESEARCH FOR INCURABLE BLOOD DISORDERS
- UIC JOINS FORCES WITH HARVARD, MAYO CLINIC TO BATTLE BONE MARROW DISORDERS
- MPD GENE MUTATION DISCOVERED!
- AFTER DISCOVERING THE JAK2 MUTATION: NEXT STEPS IN DEVELOPING TARGETED TREATMENTS FOR PV, ET AND MF
- BIKE RIDE FUND-RAISER IN MEMORY OF BELMONT CYCLIST
- UIC RECEIVES $20 MILLION NCI GRANT TO RESEARCH BLOOD DISORDERS
- NOVARTIS DRUG
- GLEEVEC(R) APPROVED IN THE US FOR FIVE RARE LIFE-THREATENING DISORDERS WITH LIMITED TREATMENT OPTIONS
- STUDY LINKS ESAS TO HIGHER LEUKEMIA RISK FOR SOME
- DISCOVERY OF A NEW MUTATION IN JAK2V617F NEGATIVE MYELOFIBROSIS PATIENTS
- UNIVERSITY OF UTAH TO INVESTIGATE BLOOD DISORDERS
- RESEARCHERS ADVANCING BLOOD CANCER THERAPIES RECEIVE $42.75 MILLION IN GRANTS FROM THE LEUKEMIA & LYMPHOMA SOCIETY
- EXELIXIS WINNING PHASE I RACE
- NOVARTIS ENTERS INTO PARTNERSHIP WITH INCYTE
- GENE MUTATION PREDICTS OUTCOME IN BLOOD DISORDER
- EXELIXIS REPORTS DATA FROM ONGOING PHASE 1 STUDY OF XL019 TO TREAT MYELOFIBROSIS – UPDATE
- TOP SCIENTISTS TO RECEIVE PRESTIGIOUS AWARDS FROM THE AMERICAN SOCIETY OF HEMATOLOGY
- JAK2 INHIBITOR SHOWS POTENT ACTIVITY IN CELLS FROM MPD PATIENTS
- TARGEGEN ANNOUNCES INITIATION OF CLINICAL TRIAL OF JAK2 INHIBITOR TG101348 IN MYELOPROLIFERATIVE DISEASE PATIENTS
- CYTOPIA NOMINATES JAK2 CLINICAL CANDIDATE FOR MYELOPROLIFERATIVE DISORDERS
- INCYTE REPORTS PROGRESS IN MULTIPLE CLINICAL PROGRAMS AND EXPANDS JAK INHIBITOR PROGRAM
- UCSD, TARGEGEN TEAM-UP ON BLOOD DISEASE TREATMENT
- REQUEST FOR PROPOSALS
- CYTOPIA APPOINTS STUDY CHAIRMAN FOR JAK2 CLINICAL TRIAL
- WATCH THE WEST PALM BEACH PATIENT SYMPOSIUM PRESENTATIONS
- SEEKING PATIENTS FOR FAMILIAL MPN STUDY
- CEMM IDENTIFIES INHERITED SUSCEPTIBILITY FOR A BLOOD MALIGNANCY
NEWS